http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#Head http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#assertion http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#provenance http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#pubinfo http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#assertion http://purl.obolibrary.org/obo/DOID_1040 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1040 http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB06650 http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association http://www.w3.org/2000/01/rdf-schema#label chronic lymphocytic leukemia cll arzerra ofatumumab is indicated in combination with chlorambucil for the treatment of previously untreated patients with cll for whom fludarabine based therapy is considered inappropriate see clinical studies 14 1 in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed cll see clinical studies 14 2 for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive cll see clinical studies 14 3 for the treatment of patients with cll refractory to fludarabine and alemtuzumab see clinical studies 14 4 arzerra ofatumumab is a cd2 directed cytolytic monoclonal antibody indicated for the treatment of chronic lymphocytic leukemia cll 1 in combination with chlorambucil for the treatment of previously untreated patients with cll for whom fludarabine based therapy is considered inappropriate in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed cll for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive cll for the treatment of patients with cll refractory to fludarabine and alemtuzumab http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB06650 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#provenance http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#pubinfo http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#sig http://purl.org/nanopub/x/hasSignature FKvGJ9o9bSfijSgwpIvb6s1Y90NuK6aE4jihBMEOzY+BJwpBcQB/9P7/ugJzvpKRmG0qSvfsSZ9+lSj7v4OY+Zgz2d+c3ZvBfOdUWwrR+DrWWdDA17qdqXGKyEheG/+vFTlWIe1ftC37KQsNBqymY1FKmRIOCXfXKeBE7YVhrdY= http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE http://purl.org/dc/terms/created 2021-07-03T14:56:16.700+02:00 http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs